



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

MALISSEN et al

Atty. Ref.: 3665-113

Serial No. 10/502,332

Group: 1632

Filed: July 23, 2004

Examiner: TON

For: MUTATED GENE CODING FOR A LAT PROTEIN AND
THE BIOLOGICAL APPLICATIONS THEREOF

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 15, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of

each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - a) The required Statement made in item 8 below; or
 - b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - b) The required Statement is stated in item 8 below.
- 8. Statement under 37 CFR 1.97(e)
 - a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

3665-113

SERIAL NO.

10/502,332

APPLICANT

MALISSEN et al

FILING DATE

July 23, 2004

GROUP

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
WO 99/32627	7/1999	WO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Genton et al., The Journal of Immunology, 2006, 177:2285-2293 "The Th2 lymphoproliferation developing in LatY136F mutant mice triggers polyclonal B cell activation and systemic autoimmunity"
	Sommers et al, "Knock-in mutation of the distal four tyrostines of linker for activation of T cells blocks murine T cell development", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 194, no. 2, 16 July 2001, pp. 135-142.
	Aguardo et al, "Induction of T Helper Type 2 Immunity by a Point Mutation in the LAT Adaptor", SCIENCE, vol. 296, no. 5575, 2002, pp. 2036-2040.
	Sommers et al, "A LAT Mutation That Inhibits T Cell Development Yet Induces Lymphoproliferation", SCIENCE, vol. 296, No. 5575, 2002, pp. 2040-2043.
	Samelson et al, "Studies on the Adapter Molecule LAT", COLD SPRING SYMPOSIA ON QUANTITATIVE BIOLOGY, BIOLOGICAL LABORATORY, COLD SPRING HARBOR, NY, US, no. 64, 1999, pp. 259-263.
	Lin et al, "Identification of the Minimal Tyrosine Residues Required for Linker for Activation of T Cell Function", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 31, 3 August 2001, pp. 29588-29595.
	Zhang et al, "Association of Grb2, Gads, and Phospholipase C γ with Phosphorylated LAT Tyrosine Residues", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 30, 28 July 2000, pp. 23355-23361.
	Zhang et al, "Essential Role of LAT in T Cell Development", IMMUNITY, vol. 10, no. 3, March 1999, pp. 323-332.
	Saitoh et al, "LAT Is Essential for Fc ϵ RI-Mediated Mast Cell Activation", IMMUNITY, vol. 12, no. 5, May 2000, pp. 525-535.

*Examiner		Date Considered
-----------	--	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)